Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM2POGY)

Drug Name
AMG 509 Drug Info
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM2POGY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Metalloreductase STEAP1 (STEAP1) TT9E64S STEA1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Metalloreductase STEAP1 (STEAP1) DTT STEAP1 7.624 6.375 5.75 6.375
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Prostate
The Studied Disease Prostate cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Metalloreductase STEAP1 (STEAP1) DTT STEAP1 1.46E-02 0.78 1.22
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04221542) Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Amgen.